FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Mainolfi Nello				2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Kymera Therapeutics, Inc.</u> [ KYMR ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Widnioni iveno													-		10% Owner			
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 07/01/2024							Officer     below)	(give title		Other (s elow)	pecity		
C/O KYMERA THERAPEUTICS, INC.					0//01/2024						Chief Executive Officer							
500 NORTH BEACON STREET, 4TH FLOOR				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)					-									Form f	iled by One	Reporting	Persor	.
WATER	TOWN M	IA	02472											Form f Persor	iled by More	than On	Repor	ting
(City)	(\$	state)	(Zip)		Rı	ule	10b	5-1(c)	Tran	sact	ion Ind	ication	•					
												nade pursua 0b5-1(c). Se		ract, instruction 10.	n or written p	lan that is	ntended	to
Table I. New Positive Consulting Assuring Dispersed of an Denofficially Consult																		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,		, Trans	Transaction Disposed (		ties Acquired (A) or d Of (D) (Instr. 3, 4 and		Benefici Owned	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									v	Amount	(A) o (D)	r Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 07/01/			1/202	24 M 18,773 A \$5.33 649,959		9,959	D											
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
			(	e.g., p	outs,	calls	s, wa	arrants	s, optio	ns, c	onverti	ble secu	irities)	1				
1. Title of Derivative Security  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date Execution Date, if any (Month/Day/Year)			ate,	4. Transaction Code (Instr. 8)		of I		Expiration	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Own For Dire or I (I) (	nership n: ct (D) ndirect nstr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$5.33	07/01/2024			М			18,773	(1)		05/13/2030	Common Stock	18,773	\$0.00	288,456	5	D	

## **Explanation of Responses:**

1. The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of May 14, 2020, subject to the reporting person's continued employment through each vesting date.

/s/ Bruce N. Jacobs, as Attorney-in-Fact

07/01/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.